ArticleScientific reports2026
Pan-cancer analysis reveals the oncogenic and immunomodulatory roles of PTGFRN across human cancers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysregulated adult hippocampal neurogenesis in major depressive disorder.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of the prostaglandin F2 receptor negative regulator (PTGFRN) in tumor biology remains incompletely understood. This study aimed to perform a comprehensive pan-cancer analysis to elucidate the functions of PTGFRN in tumor progression and its potential immunomodulatory effects. Utilizing data from the cancer genome atlas (TCGA) and the genotype-tissue expression (GTEx) project, we analyzed PTGFRN expression profiles, genetic alterations (including mutations, copy number variations, and DNA methylation), and its prognostic significance across multiple cancer types. Pathway enrichment analysis was conducted using the R package "clusterProfiler." The correlation between PTGFRN expression and immune cell infiltration levels within the tumor microenvironment was assessed via the TIMER2 database. PTGFRN was significantly overexpressed in a wide range of cancers, and its elevated expression was consistently associated with poorer patient prognosis. Furthermore, pan-cancer analysis revealed that PTGFRN expression is linked to an immunosuppressive tumor microenvironment, showing a positive correlation with immunosuppressive cells such as cancer-associated fibroblasts and a negative correlation with anti-tumor effector cells like CD8⁺ T cells. Functional validation in lung adenocarcinoma (LUAD) cells confirmed that PTGFRN acts as an oncogene, enhancing proliferative, migratory, and invasive capabilities. Our findings establish PTGFRN as a potential prognostic biomarker across cancer types. Its overexpression is indicative of an immunosuppressive tumor microenvironment, positioning PTGFRN as a promising therapeutic target for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.